Business Description
Supernus Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US8684591089
Total Employee Number:
778Compare
Compare
Traded in other countries / regions
SUPN.USAS49.Germany0LB2.UK Index Membership
Russell 2000Russell 3000 IPO Date
2012-05-01Description
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 9.26 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -2.21 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 4.73 | |||||
Beneish M-Score | -2.34 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.6 | |||||
3-Year EBITDA Growth Rate | -32.8 | |||||
3-Year FCF Growth Rate | -24.4 | |||||
3-Year Book Growth Rate | 4.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 22.65 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 40.54 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 11.8 | |||||
9-Day RSI | 22.9 | |||||
14-Day RSI | 31.03 | |||||
3-1 Month Momentum % | 4.39 | |||||
6-1 Month Momentum % | -12.3 | |||||
12-1 Month Momentum % | 1.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.08 | |||||
Quick Ratio | 1.84 | |||||
Cash Ratio | 1.07 | |||||
Days Inventory | 277.75 | |||||
Days Sales Outstanding | 78.56 | |||||
Days Payable | 25.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.9 | |||||
Shareholder Yield % | -2.36 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.08 | |||||
Operating Margin % | -6.67 | |||||
Net Margin % | -13.23 | |||||
EBITDA Margin % | -2.19 | |||||
FCF Margin % | 2.33 | |||||
OCF Margin % | 2.4 | |||||
ROE % | -10.4 | |||||
ROA % | -7.65 | |||||
ROIC % | -5.87 | |||||
3-Year ROIIC % | 14.5 | |||||
ROC (Joel Greenblatt) % | -796.73 | |||||
ROCE % | -10.88 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 9.87 | |||||
Shiller PE Ratio | 29.12 | |||||
PS Ratio | 2.87 | |||||
PB Ratio | 2.35 | |||||
Price-to-Tangible-Book | 5.47 | |||||
Price-to-Free-Cash-Flow | 131.34 | |||||
Price-to-Operating-Cash-Flow | 127.28 | |||||
EV-to-EBIT | -17.43 | |||||
EV-to-EBITDA | -115.08 | |||||
EV-to-Forward-EBITDA | 8.83 | |||||
EV-to-Revenue | 2.51 | |||||
EV-to-Forward-Revenue | 3.23 | |||||
EV-to-FCF | 107.91 | |||||
Price-to-GF-Value | 0.95 | |||||
Price-to-Projected-FCF | 1.22 | |||||
Price-to-Median-PS-Value | 0.9 | |||||
| Price-to-Net-Current-Asset-Value | 7.41 | |||||
Earnings Yield (Greenblatt) % | -5.74 | |||||
FCF Yield % | 0.8 | |||||
Forward Rate of Return (Yacktman) % | -8.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SUPN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Supernus Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 830.438 | ||
| EPS (TTM) ($) | -1.92 | ||
| Beta | 0.6782 | ||
| 3-Year Sharpe Ratio | 0.36 | ||
| 3-Year Sortino Ratio | 0.58 | ||
| Volatility % | 32.37 | ||
| 14-Day RSI | 31.03 | ||
| 14-Day ATR ($) | 1.478097 | ||
| 20-Day SMA ($) | 45.175 | ||
| 12-1 Month Momentum % | 1.86 | ||
| 52-Week Range ($) | 41.11 - 59.68 | ||
| Shares Outstanding (Mil) | 58.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Supernus Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Supernus Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-02 | In 172 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-24 16:30 | In 167 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 | In 166 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 54 days | ||
| Wells Fargo Healthcare Conference | 2026-09-10 12:45 | 42.07 (-0.24%) | ||
| Cantor Global Healthcare Conference | 2026-09-09 14:45 | 42.43 (-2.59%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-03 08:30 | 44.63 (-1.24%) | ||
| Second quarter earnings results for 2026 | 2026-08-03 | 44.63 (-1.24%) | ||
| General meeting for 2026 | 2026-06-18 10:00 | 43.58 (+0.48%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 | 44.75 (-0.67%) |
Show
Entries
Supernus Pharmaceuticals Inc Frequently Asked Questions
What is Supernus Pharmaceuticals Inc(SUPN)'s stock price today?
The current price of SUPN is $41.64. The 52 week high of SUPN is $59.68 and 52 week low is $41.11.
When is next earnings date of Supernus Pharmaceuticals Inc(SUPN)?
The next earnings date of Supernus Pharmaceuticals Inc(SUPN) is 2026-11-04 Est..
Does Supernus Pharmaceuticals Inc(SUPN) pay dividends? If so, how much?
Supernus Pharmaceuticals Inc(SUPN) does not pay dividend.
Guru Commentaries on NAS:SUPN
Aristotle Small Cap Equity Fund
Bullish
2025 Q3
Aristotle Small Cap Equity Fund
· 98 holdings
What the manager wrote
Supernus Pharmaceuticals is a Maryland-based specialty pharmaceutical company focused on developing drugs to treat central nervous system diseases. The stock benefitted from strong quarterly results, beating analyst expectations, alongside raising fiscal year 2025 forecasts. We continue to maintain our position as we believe the company’s differentiated product pipeline, along with its existing neurology products, provides strong growth potential with attractive profitability and free cash flow generation capabilities.
2025 Q3
THIRD AVENUE SMALL-CAP VALUE FUND
· 35 holdings
What the manager wrote
Supernus Pharmaceuticals is benefitting from the strength of its financial position, current profitability, an expanding neurology drug portfolio, and a strong capital allocation framework that led to an attractive acquisition completed during the quarter. The company is perceived to have a very attractive underlying asset base and a decent probability of favorable near-term resource conversion events, which aligns with the Fund's strategy of investing in companies undergoing positive metamorphosis.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers